Provides Update on Strategy to Acquire Veterinary Clinics for Immediate Revenue Generation and
New Sales Channel for Veterinary Therapies
Blogcast Scheduled for Tuesday, September 21st at 10:00 am PDT
SAN DIEGO, Sept. 16, 2010 (GLOBE NEWSWIRE) -- Entest BioMedical, Inc. (OTCBB:ENTB) announced that Chairman and CEO David Koos will be hosting a blogcast on Tuesday, September 21, 2010 at 10:00 a.m. PDT, during which the Company will discuss developments related to its immuno-therapeutic cancer vaccine for dogs, ImenVax™. Areas to be covered include:
a) ImenVax's™ projected timeline to commercialization and key milestones;
b) The addressable market for the company's veterinary therapies; and
c) The Company's plans regarding acquisitions of veterinary clinics including their potential for generating near term revenue and as a distribution channel for the company's veterinary therapies;
David Koos, Chairman & CEO of Entest BioMedical, stated, "We have spent the last several months laying the groundwork for near term commercialization of ImenVax™. At the same time, we are moving forward aggressively with our acquisition strategy, which will serve the dual purpose of providing immediate cash flow to offset our costs related to safety studies and clinical trials, while providing an effective new distribution channel for our veterinary therapies. We look forward to updating our shareholders and addressing any questions regarding Entest's business model and our 'veterinary first' approach. We are very excited about our progress and believe this will translate into meaningful value for our shareholders."
Those interested in participating in the blogcast can do so by going to http://entb.net/blog.html.
About Entest BioMedical Inc.:
Entest BioMedical is a developer of veterinary medicines that harness the animal's own reparative/immunological mechanisms. The company's products include immunotherapeutic cancer vaccines for canines (ImmenVax™ I, II & III) and a stem cell therapy treatment for Chronic Obstructive Pulmonary Disease (COPD) in thoroughbred race horses (ENT-576™). The company's immuno-therapeutic cancer vaccine utilizes an encapsulation device as the vaccine delivery system and requires a simple implant procedure. The immuno-therapeutic cancer vaccine utilizes the animals own cancer cells in order to induce an immune response. The company's proprietary ENT-576™ program for COPD incorporates "homing" stimulator technology that directs stem cells to diseased lung tissue. This approach could cause damaged tissue to regenerate with potential to alleviate symptoms and reverse lung damage.
Disclaimer
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.